Electronic Cigarette Use in 12 European Countries: Results From the TackSHS Survey.


Journal

Journal of epidemiology
ISSN: 1349-9092
Titre abrégé: J Epidemiol
Pays: Japan
ID NLM: 9607688

Informations de publication

Date de publication:
05 06 2023
Historique:
medline: 6 6 2023
pubmed: 16 11 2021
entrez: 15 11 2021
Statut: ppublish

Résumé

Limited data on electronic cigarette prevalence, patterns, and settings of use are available from several European countries. Within the TackSHS project, a face-to-face survey was conducted in 2017-2018 in 12 European countries (Bulgaria, England, France, Germany, Greece, Ireland, Italy, Latvia, Poland, Portugal, Romania and Spain). Overall, 11,876 participants, representative of the population aged ⩾15 years in each country, provided information on electronic cigarette. 2.4% (95% confidence interval [CI], 2.2-2.7%) of the subjects (2.5% among men and 2.4% among women; 0.4% among never, 4.4% among current- and 6.5% among ex-smokers) reported current use of electronic cigarette, ranging from 0.6% in Spain to 7.2% in England. Of the 272 electronic cigarette users, 52.6% were dual users (ie, users of both electronic and conventional cigarettes) and 58.8% used liquids with nicotine. In all, 65.1% reported using electronic cigarette in at least one indoor setting where smoking is forbidden; in particular, at workplaces (34.9%) and bars and restaurants (41.5%). Multivariable logistic regression analysis showed that electronic cigarette use was lower among older individuals (P for trend <0.001) and higher among individuals with high level of education (P for trend = 0.040). Participants from countries with higher tobacco cigarette prices more frequently reported electronic cigarette use (odds ratio 3.62; 95% CI, 1.80-7.30). Considering the whole adult population of these 12 European countries, more than 8.3 million people use electronic cigarettes. The majority of users also smoked conventional cigarettes, used electronic cigarettes with nicotine, and consumed electronic cigarettes in smoke-free indoor areas.

Sections du résumé

BACKGROUND
Limited data on electronic cigarette prevalence, patterns, and settings of use are available from several European countries.
METHODS
Within the TackSHS project, a face-to-face survey was conducted in 2017-2018 in 12 European countries (Bulgaria, England, France, Germany, Greece, Ireland, Italy, Latvia, Poland, Portugal, Romania and Spain). Overall, 11,876 participants, representative of the population aged ⩾15 years in each country, provided information on electronic cigarette.
RESULTS
2.4% (95% confidence interval [CI], 2.2-2.7%) of the subjects (2.5% among men and 2.4% among women; 0.4% among never, 4.4% among current- and 6.5% among ex-smokers) reported current use of electronic cigarette, ranging from 0.6% in Spain to 7.2% in England. Of the 272 electronic cigarette users, 52.6% were dual users (ie, users of both electronic and conventional cigarettes) and 58.8% used liquids with nicotine. In all, 65.1% reported using electronic cigarette in at least one indoor setting where smoking is forbidden; in particular, at workplaces (34.9%) and bars and restaurants (41.5%). Multivariable logistic regression analysis showed that electronic cigarette use was lower among older individuals (P for trend <0.001) and higher among individuals with high level of education (P for trend = 0.040). Participants from countries with higher tobacco cigarette prices more frequently reported electronic cigarette use (odds ratio 3.62; 95% CI, 1.80-7.30).
CONCLUSION
Considering the whole adult population of these 12 European countries, more than 8.3 million people use electronic cigarettes. The majority of users also smoked conventional cigarettes, used electronic cigarettes with nicotine, and consumed electronic cigarettes in smoke-free indoor areas.

Identifiants

pubmed: 34776500
doi: 10.2188/jea.JE20210329
pmc: PMC10165220
doi:

Substances chimiques

Nicotine 6M3C89ZY6R

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

276-284

Références

J Epidemiol. 2022 Mar 5;32(3):139-144
pubmed: 33456019
Gac Sanit. 2016 Nov - Dec;30(6):432-437
pubmed: 27198921
N Engl J Med. 2019 Feb 14;380(7):678-679
pubmed: 30699299
Tob Control. 2018 May;27(3):254-257
pubmed: 28601841
Am J Public Health. 2021 Feb;111(2):230-246
pubmed: 33351653
Tob Control. 2017 Mar;26(e1):e19-e22
pubmed: 27609779
Tob Control. 2021 Jan;30(1):49-56
pubmed: 32123139
JAMA Netw Open. 2018 Jul 6;1(3):e180789
pubmed: 30646032
Int J Environ Res Public Health. 2017 Oct 11;14(10):
pubmed: 29019917
Tob Control. 2020 Mar;29(2):148-152
pubmed: 30659103
Int J Environ Res Public Health. 2016 May 03;13(5):
pubmed: 27153077
Tob Induc Dis. 2020 Nov 03;18:91
pubmed: 33192223
Tob Control. 2017 Aug 17;:
pubmed: 28818839
Int J Environ Res Public Health. 2021 Feb 16;18(4):
pubmed: 33669394
JAMA Pediatr. 2017 Aug 1;171(8):788-797
pubmed: 28654986
Dtsch Arztebl Int. 2016 Dec 16;113(50):847-854
pubmed: 28098063
J Epidemiol. 2021 Feb 5;31(2):145-151
pubmed: 32249267
Tob Control. 2017 Jan;26(1):98-104
pubmed: 27220621
Addiction. 2016 Nov;111(11):2032-2040
pubmed: 27338716
Gac Sanit. 2020 Jan - Feb;34(1):77-82
pubmed: 31558386
Tob Control. 2015 Sep;24(5):442-8
pubmed: 24935441
Tumori. 2020 Apr 26;:300891620915784
pubmed: 32338200
Tob Induc Dis. 2018 Aug 05;16:A1
pubmed: 31516457
Eur Respir J. 2020 Dec 24;56(6):
pubmed: 33361450
Cochrane Database Syst Rev. 2020 Oct 14;10:CD010216
pubmed: 33052602
Am J Prev Med. 2020 Feb;58(2):182-190
pubmed: 31859175
Addiction. 2020 May;115(5):961-974
pubmed: 31621131
Eur Respir J. 2021 Jan 21;57(1):
pubmed: 33154031
J Epidemiol. 2022 Mar 5;32(3):131-138
pubmed: 33342937
Nicotine Tob Res. 2014 Dec;16(12):1541-8
pubmed: 25082832
N Engl J Med. 2021 Apr 22;384(16):1573-1576
pubmed: 33725431
Tob Control. 2019 Jan;28(1):50-59
pubmed: 29695458
Nicotine Tob Res. 2016 May;18(5):724-9
pubmed: 26438649
Prev Med. 2018 Nov;116:13-18
pubmed: 30144487
Environ Res. 2017 Oct;158:685-690
pubmed: 28734255

Auteurs

Silvano Gallus (S)

Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS.

Alessandra Lugo (A)

Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS.

Chiara Stival (C)

Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS.

Sonia Cerrai (S)

Epidemiology and Health Research Lab, Institute of Clinical Physiology, National Research Council of Italy (IFC-CNR).

Luke Clancy (L)

TobaccoFree Research Institute Ireland.

Filippos T Filippidis (FT)

Department of Primary Care and Public Health, Imperial College London.

Giuseppe Gorini (G)

Oncologic Network, Prevention and Research Institute (ISPRO).

Maria José Lopez (MJ)

Agència de Salut Pública de Barcelona.
Departament de Ciències Experimentals i de la Salut (DCEXS), Universitat Pompeu Fabra.
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP).
Sant Pau Institute of Biomedical Research (IIB Sant Pau).

Ángel López-Nicolás (Á)

Polytechnic University of Cartagena (UPCT).

Sabrina Molinaro (S)

Epidemiology and Health Research Lab, Institute of Clinical Physiology, National Research Council of Italy (IFC-CNR).

Anna Odone (A)

School of Medicine, University Vita-Salute San Raffaele.
Department of Public Health, Experimental and Forensic Medicine, University of Pavia.

Joan B Soriano (JB)

Hospital Universitario La Princesa (IISP).
Consortium for Biomedical Research in Respiratory Diseases (CIBERES).

Olena Tigova (O)

Consortium for Biomedical Research in Respiratory Diseases (CIBERES).
Tobacco Control Research Group, Epidemiology and Public Health Research Programme, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL.
Tobacco Control Unit, WHO collaborating center on tobacco control, Institut Català d'Oncologia-ICO.
School of Medicine and Health Sciences, Campus of Bellvitge, Universitat de Barcelona.

Piet A van den Brandt (PA)

Maastricht University Medical Centre, GROW- School for Oncology and Developmental Biology, Department of Epidemiology.
Maastricht University Medical Centre, CAPHRI- School for Public Health and Primary Care, Department of Epidemiology.

Constantine I Vardavas (CI)

Hellenic Cancer Society.
School of Medicine, University of Crete.

Esteve Fernandez (E)

Consortium for Biomedical Research in Respiratory Diseases (CIBERES).
Tobacco Control Research Group, Epidemiology and Public Health Research Programme, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL.
Tobacco Control Unit, WHO collaborating center on tobacco control, Institut Català d'Oncologia-ICO.
School of Medicine and Health Sciences, Campus of Bellvitge, Universitat de Barcelona.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH